1
|
Xu XM, Shi R, Li W, Zhang X, Chen S, Wang ZL, Wang X. One-Pot Synthesis of Diverse Isoindolobenzoxazinone and Isoindoloquinazolinone Derivatives through a Transition Metal-Free Cascade Cyclization. J Mol Struct 2023. [DOI: 10.1016/j.molstruc.2023.135105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
2
|
Kotb AR, Abdallah AE, Elkady H, Eissa IH, Taghour MS, Bakhotmah DA, Abdelghany TM, El-Zahabi MA. Design, synthesis, anticancer evaluation, and in silico ADMET analysis of novel thalidomide analogs as promising immunomodulatory agents †. RSC Adv 2023; 13:10488-10502. [PMID: 37021105 PMCID: PMC10069230 DOI: 10.1039/d3ra00066d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Accepted: 03/27/2023] [Indexed: 04/05/2023] Open
Abstract
Immunomodulatory medications like thalidomide and its analogs prevent the production of some proinflammatory cytokines linked to cancer. A new series of thalidomide analogs were designed and synthesized in order to develop potential antitumor immunomodulatory agents. The antiproliferative activities of the new candidates against a panel of three human cancer cell lines (HepG-2, PC3 and MCF-7) were assessed in comparison to thalidomide as a positive control. The obtained results showed the relative significant potency of 18f (IC50 = 11.91 ± 0.9, 9.27 ± 0.7, and 18.62 ± 1.5 μM) and 21b (IC50 = 10.48 ± 0.8, 22.56 ± 1.6, and 16.39 ± 1.4 μM) against the mentioned cell lines, respectively. These results were comparable to thalidomide (IC50 = 11.26 ± 0.54, 14.58 ± 0.57, and 16.87 ± 0.7 μM, respectively). To see to what extent the biological properties of the new candidates are relative to those of thalidomide, the effects of 18f and 21b on the expression levels of TNF-α, CASP8, VEGF, and NF-κB P65 were evaluated. Significant reductions in the proinflammatory TNF-α, VEGF, and NF-κB P65 levels in HepG-2 cells were observed after exposure to compounds 18f and 21b. Furthermore, a sharp increase in CASP8 levels was detected. The obtained results revealed that 21b is of greater significance than thalidomide in TNF-α and NF-κB P65 inhibition. The in silico ADMET and toxicity studies showed that most of tested candidates have a good profile of drug-likeness and low toxicity potential. Novel thalidomide analogs as anticancer immunomodulatory agents.![]()
Collapse
Affiliation(s)
- Anas Ramadan Kotb
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar UniversityCairo11884Egypt
| | - Abdallah E. Abdallah
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar UniversityCairo11884Egypt
| | - Hazem Elkady
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar UniversityCairo11884Egypt
| | - Ibrahim H. Eissa
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar UniversityCairo11884Egypt
| | - Mohammed S. Taghour
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar UniversityCairo11884Egypt
| | - Dina Abed Bakhotmah
- Department of Chemistry, Faculty of Science, King Abdulaziz UniversityJeddahSaudi Arabia
| | - Tamer M. Abdelghany
- Department of Pharmacology& Toxicology, Faculty of Pharmacy, Al-Azhar UniversityCairoEgypt
- Department of Pharmacology& Toxicology, Faculty of Pharmacy, Heliopolis University for Sustainable DevelopmentCairoEgypt
| | - Mohamed Ayman El-Zahabi
- Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar UniversityCairo11884Egypt
| |
Collapse
|
3
|
Sun B, Liu X, Ji T, Zhan X, Mao L, Deng P, Shi L. Design, synthesis, and biological activity of novel pomalidomide linked with diphenylcarbamide derivatives. HETEROCYCL COMMUN 2022. [DOI: 10.1515/hc-2022-0155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Abstract
Based on 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione as a raw material, a series of novel pomalidomide linked with diphenylcarbamide derivatives were synthesized through several step reactions of substitution, click reaction, and addition reaction. The structures of these compounds were confirmed by 1H NMR, 13C NMR, and MS. We discovered that some of the compounds are capable of suppressing indoleamine pyrrole-2,3-dioxygenase-1 activities in in vitro experiments, in which the inhibitory activity of 5b reached the level of benefits.
Collapse
Affiliation(s)
- Bin Sun
- College of Chemistry, Chemical Engineering and Materials Science, Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Universities of Shandong, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Shandong Provincial Key Laboratory of Clean Production of Fine Chemicals, Shandong Normal University, 88 East Wenhua Road , Jinan 250014 , PR China
| | - Xiaofei Liu
- Key Laboratory of Agro-Products Processing Technology of Shandong Province, Key Laboratory of Novel Food Resources Processing, Ministry of Agriculture, Institute of Agro-Food Science and Technology, Shandong Academy of Agricultural Sciences , Jinan 250100 , China
- Jinan Asia Pharma Tech Co. Ltd , Jinan 250101 , China
| | - Tao Ji
- Key Laboratory of Agro-Products Processing Technology of Shandong Province, Key Laboratory of Novel Food Resources Processing, Ministry of Agriculture, Institute of Agro-Food Science and Technology, Shandong Academy of Agricultural Sciences , Jinan 250100 , China
- Jinan Asia Pharma Tech Co. Ltd , Jinan 250101 , China
| | - Xiaoguang Zhan
- Key Laboratory of Agro-Products Processing Technology of Shandong Province, Key Laboratory of Novel Food Resources Processing, Ministry of Agriculture, Institute of Agro-Food Science and Technology, Shandong Academy of Agricultural Sciences , Jinan 250100 , China
- Jinan Asia Pharma Tech Co. Ltd , Jinan 250101 , China
| | - Longfei Mao
- Key Laboratory of Agro-Products Processing Technology of Shandong Province, Key Laboratory of Novel Food Resources Processing, Ministry of Agriculture, Institute of Agro-Food Science and Technology, Shandong Academy of Agricultural Sciences , Jinan 250100 , China
- Jinan Asia Pharma Tech Co. Ltd , Jinan 250101 , China
| | - Peng Deng
- Key Laboratory of Agro-Products Processing Technology of Shandong Province, Key Laboratory of Novel Food Resources Processing, Ministry of Agriculture, Institute of Agro-Food Science and Technology, Shandong Academy of Agricultural Sciences , Jinan 250100 , China
| | - Lin Shi
- Department of Ultrasound Diagnosis and Treatment Department, Shandong Provincial Hospital Affiliated to Shandong First Medical University , Jinan 250021 , China
| |
Collapse
|
4
|
Guo Y, Wang X, Wang Z, Mao L, Wang J, Peng L, Xu G. Synthesis and Anti-Tumor Effects of Novel Pomalidomide Derivatives Containing Urea Moieties. Pharmaceuticals (Basel) 2022; 15:ph15121479. [PMID: 36558930 PMCID: PMC9785895 DOI: 10.3390/ph15121479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Revised: 11/25/2022] [Accepted: 11/25/2022] [Indexed: 11/29/2022] Open
Abstract
In order to explore novel immunomodulatory agents as anti-tumor drugs, we designed and synthesized a series of new pomalidomide derivatives containing urea moieties. Interestingly, in vitro biological experiments performed in several cancer cell lines showed that some of them displayed potent anti-tumor ability. These novel compounds 5a-5e and 6a-6e demonstrated the best cell growth inhibitive activity in human breast cancer cell lines MCF-7, but weaker inhibitive activity in human hepatocellular carcinoma cell lines Huh7. Moreover, compound 5d had the most powerful effects in this study, with an IC50 value of 20.2 μM in MCF-7. Further study indicated that compound 5d could inhibit cell growth and induce cell death in a concentration-dependent manner. Besides, compound 5d increased cellular ROS levels and induced DNA damage, thereby potentially leading to cell apoptosis. These observations suggest that the novel pomalidomide derivatives containing urea moieties may be worth further investigation to generate potential anti-tumor drugs.
Collapse
Affiliation(s)
- Yajie Guo
- The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China
| | - Xi Wang
- School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, China
| | - Zhenzhen Wang
- School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, China
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, China
- Key Laboratory of Agro-Products Processing Technology of Shandong Province, Key Laboratory of Novel Food Resources Processing Ministry of Agriculture, Institute of Agro-Food Science and Technology Shandong Academy of Agricultural Sciences, Jinan 250100, China
| | - Longfei Mao
- School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, China
| | - Jiahao Wang
- School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, China
| | - Lizeng Peng
- Key Laboratory of Agro-Products Processing Technology of Shandong Province, Key Laboratory of Novel Food Resources Processing Ministry of Agriculture, Institute of Agro-Food Science and Technology Shandong Academy of Agricultural Sciences, Jinan 250100, China
- Correspondence: (L.P.); (G.X.)
| | - Guiqing Xu
- School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, China
- Correspondence: (L.P.); (G.X.)
| |
Collapse
|
5
|
Muvvala S, Kumari K, Miriyala V, Mogili P, Chidara S, Maddirala SJ, Saxena A, Behera M. Microwave‐Assisted Reductive Amination of 2‐Carboxybenzaldehydes with Amines for the Synthesis of N‐Substituted Isoindolin‐1‐one. ChemistrySelect 2022. [DOI: 10.1002/slct.202202500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Subhashini Muvvala
- Chemistry services, Aragen Life Sciences, Survey Nos:125 (part) & 126, IDA Mallapur Hyderabad 500076 Telangana State India
- Department of Engineering Chemistry Andhra University Visakhapatnam Andhra Pradesh 530003 India
| | - Krishnaiah Kumari
- Chemistry services, Aragen Life Sciences, Survey Nos:125 (part) & 126, IDA Mallapur Hyderabad 500076 Telangana State India
| | - Venkatesh Miriyala
- Chemistry services, Aragen Life Sciences, Survey Nos:125 (part) & 126, IDA Mallapur Hyderabad 500076 Telangana State India
| | - Padma Mogili
- Department of Engineering Chemistry Andhra University Visakhapatnam Andhra Pradesh 530003 India
| | - Sridhar Chidara
- Chemistry services, Aragen Life Sciences, Survey Nos:125 (part) & 126, IDA Mallapur Hyderabad 500076 Telangana State India
| | - Shambabu Joseph Maddirala
- Chemistry services, Aragen Life Sciences, Survey Nos:125 (part) & 126, IDA Mallapur Hyderabad 500076 Telangana State India
| | - Abhishek Saxena
- Chemistry services, Aragen Life Sciences, Survey Nos:125 (part) & 126, IDA Mallapur Hyderabad 500076 Telangana State India
| | - Manoranjan Behera
- Chemistry services, Aragen Life Sciences, Survey Nos:125 (part) & 126, IDA Mallapur Hyderabad 500076 Telangana State India
| |
Collapse
|
6
|
Cheng YN, Sun L, Meng H, Jiang Z, Zhang Z, Yun Y, Wang X, Yan J, Yang X, Zhou H, Li H. Structure-Activity Studies of N-Heterocyclic Benzoyl Arylamine Derivatives Led to a Highly Fungicidal Candidate against Gaeumannomyces graminis var. tritici and Four Fusarium Wheat Pathogens. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2022; 70:10305-10315. [PMID: 35950372 DOI: 10.1021/acs.jafc.2c03455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Wheat root diseases can seriously reduce yields and quality of wheat. 1,2,4-Triazole benzoyl arylamine derivatives previously showed good activities against some wheat root fungal pathogens. To further systematically disclose the structure-activity relationship, a series of benzoyl arylamines were designed and prepared. Their structures were characterized and fungicidal activities against Gaeumannomyces graminis var. tritici and Fusarium graminearum were evaluated. The results indicated that the structure of the N-heterocyclic group and the substituted group and their position on the benzamide scaffold had an important influence on the activities, as predicted. Finally, compound 18f was found to show excellent activities against G. graminis var. tritici, F. graminearum, Fusarium culmorum, Fusarium pseudograminearum, and Fusarium moniliforme with half-maximum effective concentrations of 0.002, 0.093, 0.011, 0.881, and 0.287 μg/mL, respectively. These results proposed that compound 18f deserved serious consideration as a novel fungicide candidate for the control of wheat root diseases.
Collapse
Affiliation(s)
- Yi-Nan Cheng
- Plant Protection College of Henan Agricultural University, Zhengzhou 450002, People's Republic of China
| | - Liansheng Sun
- Plant Protection College of Henan Agricultural University, Zhengzhou 450002, People's Republic of China
| | - Haoguang Meng
- Plant Protection College of Henan Agricultural University, Zhengzhou 450002, People's Republic of China
| | - Zhenhua Jiang
- Plant Protection College of Henan Agricultural University, Zhengzhou 450002, People's Republic of China
| | - Zhijia Zhang
- Plant Protection College of Henan Agricultural University, Zhengzhou 450002, People's Republic of China
| | - Yuanyuan Yun
- Plant Protection College of Henan Agricultural University, Zhengzhou 450002, People's Republic of China
| | - Xiafei Wang
- Plant Protection College of Henan Agricultural University, Zhengzhou 450002, People's Republic of China
| | - Jingming Yan
- Plant Protection College of Henan Agricultural University, Zhengzhou 450002, People's Republic of China
| | - Xifa Yang
- Plant Protection College of Henan Agricultural University, Zhengzhou 450002, People's Republic of China
| | - Haifeng Zhou
- Plant Protection College of Henan Agricultural University, Zhengzhou 450002, People's Republic of China
| | - Honglian Li
- Plant Protection College of Henan Agricultural University, Zhengzhou 450002, People's Republic of China
| |
Collapse
|
7
|
Richardson PG, Mateos MV, Vangsted AJ, Ramasamy K, Abildgaard N, Ho PJ, Quach H, Bahlis NJ. The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease. Expert Rev Proteomics 2022; 19:235-246. [PMID: 36342226 DOI: 10.1080/14789450.2022.2142564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
INTRODUCTION Insights into the mechanisms of protein homeostasis and proteasomal degradation have led to new strategies of redirecting the ubiquitin-proteasome system (UPS) to reduce or eliminate proteins or survival factors key to malignant pathobiology, multiple myeloma (MM) in particular. These strategies have enabled researchers to target proteins that were previously considered difficult to modulate by pharmacological means. AREAS COVERED This review provides a brief overview of UPS biology, particularly the role of the CRL4CRBN E3 ubiquitin ligase complex, and summarizes current strategies for co-opting the UPS, including CELMoD compounds, SNIPERs, PROTACs, and degronimids. A detailed discussion is provided on lead CELMoD compounds iberdomide and mezigdomide, which are currently being evaluated in clinical trials in patients with MM. EXPERT OPINION Since a high proportion of patients develop drug resistance, it is vital to have novel therapeutic agents for treating relapsed patients with MM more effectively. It is encouraging that the expanding pathophysiological insight into cellular signaling pathways in MM increasingly translates into the development of novel therapeutic agents such as targeted protein degraders. This holds promise for improving outcomes in MM and beyond.
Collapse
Affiliation(s)
- Paul G Richardson
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | | | | | - Karthik Ramasamy
- Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
| | - Niels Abildgaard
- Hematology Research Unit, Department of Hematology, Odense University Hospital, Odense, Denmark; and Department of Clinical Research.,Department of Clinical Research, University of Southern Denmark, Odense, Denmark
| | - P Joy Ho
- Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.,Sydney Medical School, University of Sydney, Camperdown, NSW, Australia
| | - Hang Quach
- Department of Haematology, St Vincent's Hospital, Melbourne, Australia
| | - Nizar J Bahlis
- Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
| |
Collapse
|
8
|
Zhang W, Li Y, Cui H, Su X, Xu S. One-Pot Synthesis of N-Substituted Isoindolin-1-ones via Reductive Amination/Lactamization of Methyl 2-Formylbenzoate. CHINESE J ORG CHEM 2022. [DOI: 10.6023/cjoc202202022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
9
|
Chastain DB, Golpayegany S, Henao-Martínez AF, Jackson BT, Stoudenmire LL, Bell K, Stover KR, Franco-Paredes C. Cryptococcosis in a patient with multiple myeloma receiving pomalidomide: a case report and literature review. Ther Adv Infect Dis 2022; 9:20499361221112639. [PMID: 35898694 PMCID: PMC9310278 DOI: 10.1177/20499361221112639] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Accepted: 06/23/2022] [Indexed: 11/16/2022] Open
Abstract
While overall survival with multiple myeloma (MM) has improved, patients suffer from overwhelming tumor burden, MM-associated comorbidities, and frequent relapses requiring administration of salvage therapies. As a result, this vicious cycle is often characterized by cumulative immunodeficiency stemming from a combination of disease- and treatment-related factors leading to neutropenia, T-cell deficiency, and hypogammaglobulinemia. Infectious etiologies differ based on the duration of MM and treatment-related factors, such as number of previous treatments and cumulative dose of corticosteroids. Herein, we present the case of a patient who was receiving pomalidomide without concomitant corticosteroids for MM and was later found to have cryptococcosis, as well as findings from a literature review. Most cases of cryptococcosis are reported in patients with late-stage MM, as well as those receiving novel anti-myeloma agents, such as pomalidomide, in combination with corticosteroids or following transplantation. However, it is likely cryptococcosis may be underdiagnosed in this population. Due to the cumulative immunodeficiency present in patients with MM, clinicians must be suspicious of cryptococcosis at any stage of MM.
Collapse
Affiliation(s)
- Daniel B Chastain
- Clinical Associate Professor, Department of Clinical & Administrative Pharmacy, College of Pharmacy, University of Georgia, 1000 Jefferson Street, Albany, GA 31701, USA
| | - Sahand Golpayegany
- Department of Clinical & Administrative Pharmacy, College of Pharmacy, University of Georgia, Albany, GA, USA
| | | | | | | | - Kaye Bell
- Department of Microbiology, Phoebe Putney Memorial Hospital, Albany, GA, USA
| | - Kayla R Stover
- Department of Pharmacy Practice, School of Pharmacy, University of Mississippi, Jackson, MS, USA
| | | |
Collapse
|
10
|
Charliński G, Vesole DH, Jurczyszyn A. Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma. Cancers (Basel) 2021; 13:4666. [PMID: 34572892 PMCID: PMC8468542 DOI: 10.3390/cancers13184666] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Revised: 09/14/2021] [Accepted: 09/14/2021] [Indexed: 12/20/2022] Open
Abstract
Over the past two decades, the improvement in our understanding of the biology of MM and the introduction of new drug classes, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PI), and monoclonal antibodies (MoAb), have significantly improved outcomes. The first IMiD introduced to treat MM was thalidomide. The side effects observed during treatment with thalidomide initiated work on the synthesis of IMiD analogs. Subsequently, lenalidomide and pomalidomide were developed, both with different safety profiles, and they have better tolerability than thalidomide. In 2010, the cereblon (CRBN) protein was discovered as a direct target of IMiDs. By binding to CRBN, IMiDs change the substrate specificity of the CRBN E3 ubiquitin ligase complex, which results in the breakdown of internal Ikaros and Aiolos proteins. Most clinical trials conducted, both in newly diagnosed, post-transplant maintenance and relapsed/refractory MM, report a beneficial effect of IMiDs on the extension of progression-free survival and overall survival in patients with MM. Due to side effects, thalidomide is used less frequently. Currently, lenalidomide is used at every phase of MM treatment. Lenalidomide is used in conjunction with other agents such as PIs and MoAb as induction and relapsed therapy. Pomalidomide is currently used to treat relapsed/refractory MM, also with PIs and monoclonal antibodies. Current clinical trials are evaluating the efficacy of IMiD derivatives, the CRBN E3 ligase modulators (CELMoDs). This review focuses on the impact of IMiDs for the treatment of MM.
Collapse
Affiliation(s)
- Grzegorz Charliński
- Department of Hematology, Warmian-Masurian Cancer Center of The Ministry of The Interior and Administration’s Hospital, 10-228 Olsztyn, Poland;
| | - David H. Vesole
- John Theurer Cancer Center at Hackensack Meridian School of Medicine, Hackensack, NJ 07601, USA;
| | - Artur Jurczyszyn
- Plasma Cell Dyscrasia Center, Department of Hematology, Faculty of Medicine, Jagiellonian University Medical College, 31-501 Kraków, Poland
| |
Collapse
|
11
|
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma. Oncotarget 2021; 12:1555-1563. [PMID: 34316334 PMCID: PMC8310669 DOI: 10.18632/oncotarget.27973] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2021] [Accepted: 05/13/2021] [Indexed: 12/30/2022] Open
Abstract
Multiple Myeloma (MM) is an incurable malignancy with current treatment choices primarily comprising combination regimens implemented with a risk-adapted approach. Cereblon (CRBN)-targeting immunomodulatory agents (IMiDs®) lenalidomide (LEN) and pomalidomide (POM) play a central role in combination regimens due to their pleiotropic antitumor/immunomodulatory mechanisms that synergize with many anti-myeloma approved or developmental agents. Currently, more potent next generation cereblon E3 ligase modulators (CELMoDs®) - iberdomide (IBER) and CC-92480 are in clinical development. With an expanding number of active agents/therapeutic modalities and a myriad of combinatorial possibilities, physicians and drug developers share an opportunity and challenge to combine and sequence therapies to maximize long-term patient benefit. Understanding drug mechanisms and their application in combination settings as well as the unique disease biology considerations from newly diagnosed (NDMM), relapsed/refractory (RRMM), and maintenance settings will be vital to guide the development of future MM therapies centered on a backbone of IMiD or CELMoD agents. Key aspects of drug activity are critical to consider while evaluating potential combinations: direct antitumor effects, indirect antitumor cytotoxicity, immune surveillance, and adverse side effects. In addition, the treatment journey from NDMM to early and late MM relapses are connected to genomic and immune changes associated with disease progression and acquisition of resistance mechanisms. Based on the types of combinations used and the goals of therapy, insights into mechanisms of drug activity and resistance may inform treatment decisions for patients with MM. Here we focus on the evolving understanding of the molecular mechanisms of CRBN-binding drugs and how they can be differentiated and suggest a strategic framework to optimize efficacy and safety of combinations using these agents.
Collapse
|
12
|
Afzali M, Mostafavi A, Afzali Z, Shamspur T. Designing a rapid and selective electrochemical nanosensor based on molecularly imprinted polymer on the Fe3O4/MoS2/glassy carbon electrode for detection of immunomodulatory drug pomalidomide. Microchem J 2021. [DOI: 10.1016/j.microc.2021.106039] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
13
|
Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs. Molecules 2021; 26:molecules26092525. [PMID: 33926033 PMCID: PMC8123623 DOI: 10.3390/molecules26092525] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 04/21/2021] [Accepted: 04/23/2021] [Indexed: 11/18/2022] Open
Abstract
A series of PROTACs (PROteolysis-TArgeting Chimeras) consisting of bicalutamide analogs and thalidomides were designed, synthesized, and biologically evaluated as novel androgen receptor (AR) degraders. In particular, we found that PROTAC compound 13b could successfully demonstrate a targeted degradation of AR in AR-positive cancer cells and might be a useful chemical probe for the investigation of AR-dependent cancer cells, as well as a potential therapeutic candidate for prostate cancers.
Collapse
|
14
|
Zhu L, Hu S, Chen Q, Zhang H, Fu J, Zhou Y, Bai Y, Pan Y, Shao C. Macrophage contributes to radiation-induced anti-tumor abscopal effect on transplanted breast cancer by HMGB1/TNF-α signaling factors. Int J Biol Sci 2021; 17:926-941. [PMID: 33867819 PMCID: PMC8040298 DOI: 10.7150/ijbs.57445] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2020] [Accepted: 02/13/2021] [Indexed: 02/07/2023] Open
Abstract
Objectives: The roles of innate immunity including macrophages in radiation-induced abscopal effect (RIAE) are ambiguous. In this study, we evaluated the role of macrophage in RIAE and the interaction of cytokines in tumor microenvironment after irradiation. Materials and Methods: Transplanted tumor of breast cancer cells in BalB/C mice, severe combined immunodeficiency (SCID) mice and non-obese diabetic (NOD)-SCID mice were irradiated with fractionation doses to observe anti-tumor abscopal effect. The underlying mechanism of RIAE was investigated by treating the mice with TNF-α inhibitor or macrophage depletion drug and analyzing the alteration of macrophage distribution in tumors. A co-culture system of breast cancer cells and macrophages was applied to disclose the signaling factors and related pathways involved in the RIAE. Results: The growth of nonirradiated tumor was effectively suppressed in mice with normal or infused macrophages but not in mice with insufficiency/depletion of macrophage or TNF-α inhibition, where M1-macrophage was mainly involved. Investigation of the bystander signaling factors in vitro demonstrated that HMGB1 released from irradiated breast cancer cells promoted bystander macrophages to secret TNF-α through TLR-4 pathway and further inhibited the proliferation and migration of non-irradiated cancer cells by PI3K-p110γ suppression. Conclusions: HMGB1 and TNF-α contributes to M1-macrophages facilitated systemic anti-tumor abscopal response triggered by radiotherapy in breast cancer, indicating that the combination of immunotherapy and radiotherapy may has important implication in enhancing the efficiency of tumor treatment.
Collapse
Affiliation(s)
- Lin Zhu
- Institute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China
| | - Songling Hu
- Institute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China
| | - Qianping Chen
- Institute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China
| | - Haowen Zhang
- Institute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China.,State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou 215123, China
| | - Jiamei Fu
- Department of Radiation Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China
| | - Yuchuan Zhou
- Institute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China
| | - Yang Bai
- Institute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China
| | - Yan Pan
- Institute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China
| | - Chunlin Shao
- Institute of Radiation Medicine, Shanghai Medical College, Fudan University, Shanghai 200032, China
| |
Collapse
|
15
|
El-Zahabi MA, Sakr H, El-Adl K, Zayed M, Abdelraheem AS, Eissa SI, Elkady H, Eissa IH. Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents. Bioorg Chem 2020; 104:104218. [DOI: 10.1016/j.bioorg.2020.104218] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Revised: 06/04/2020] [Accepted: 08/22/2020] [Indexed: 01/06/2023]
|
16
|
Design, synthesis and biological evaluation of thioether-containing lenalidomide and pomalidomide derivatives with anti-multiple myeloma activity. Eur J Med Chem 2020; 209:112912. [PMID: 33328101 DOI: 10.1016/j.ejmech.2020.112912] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2020] [Revised: 09/30/2020] [Accepted: 10/03/2020] [Indexed: 12/12/2022]
Abstract
Lenalidomide and its analogs are well-known for treating multiple myeloma. In this work, designed sulfide-modified lenalidomide and pomalidomide were synthesized and evaluated. The anti-proliferative activity against MM.1S cell line of 3ak (IC50 = 79 nM) was similar to lenalidomide (IC50 = 81 nM). Compared to benzylic thioether substituted lenalidomide 3a, the half-live (T1/2) of 4-F-phenyl-thioether analogs 3ak in human liver microsomes was promoted from 3 min to 416.7 min. The corresponding metabolic factor of 3ak was increased from 2.8% to 79.5%, which was slightly lower than lenalidomide (91.5%). Moreover, the IKZF1 degradation of 3y and 3ak was well related with corresponding IC50 values, which suggested the IKZF1 degradation efficiency is correlated to the responses of MM1. S cells. Furthermore, the oral administration of compounds 3y and 3ak at dosages of 60 mg/kg could delay tumor growth in female CB-17 SCID mice. This research helped to prompt the stability of thioether lenalidomide analogs, which paved the way for developing better molecules for treating multiple myeloma.
Collapse
|
17
|
Xiao D, Wang YJ, Wang HL, Zhou YB, Li J, Lu W, Jin J. Design and synthesis of new lenalidomide analogs via Suzuki cross-coupling reaction. Arch Pharm (Weinheim) 2020; 353:e1900376. [PMID: 32342558 DOI: 10.1002/ardp.201900376] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Revised: 03/26/2020] [Accepted: 03/27/2020] [Indexed: 11/09/2022]
Abstract
Lenalidomide is a cereblon modulator known for its antitumor, anti-inflammatory, and immunomodulatory properties in clinical applications. Recently, some reported lenalidomide analogs could exhibit a significant bioactivity through various modifications in the isoindolinone ring. In this study, we designed and synthesized a series of novel lenalidomide analogs on the basis of the installation of a methylene chain at the C-4 position of isoindolinone via the Suzuki cross-coupling reaction. These new compounds were further evaluated for their in vitro antiproliferative activities against two tumor cell lines (MM.1S and Mino). Specifically, compound 4c displayed the strongest antiproliferative activity against the MM.1S (IC50 = 0.27 ± 0.03 μM) and Mino (IC50 = 5.65 ± 0.58 μM) tumor cell lines. In summary, we have developed a new synthetic strategy for C-4 derivatization of lenalidomide, providing a bioactive scaffold that could be used to discover further potential antitumor lead compounds in pharmaceutical research.
Collapse
Affiliation(s)
- Donghuai Xiao
- School of Chemistry and Molecular Engineering, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, East China Normal University, Shanghai, China
| | - Yu-Jie Wang
- State Key Laboratory of Drug Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| | - Han-Lin Wang
- State Key Laboratory of Drug Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.,University of Chinese Academy of Sciences, Beijing, China.,School of Life Science and Technology, Shanghai Tech University, Shanghai, China
| | - Yu-Bo Zhou
- State Key Laboratory of Drug Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| | - Jia Li
- State Key Laboratory of Drug Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.,University of Chinese Academy of Sciences, Beijing, China.,School of Life Science and Technology, Shanghai Tech University, Shanghai, China.,Pilot National Laboratory for Marine Science and Technology (Qingdao), Open Studio for Druggability Research of Marine Natural Products, Qingdao, China
| | - Wei Lu
- School of Chemistry and Molecular Engineering, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, East China Normal University, Shanghai, China
| | - Jiyu Jin
- School of Chemistry and Molecular Engineering, Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, East China Normal University, Shanghai, China
| |
Collapse
|
18
|
Design, synthesis and biological evaluation of the thioether-containing lenalidomide analogs with anti-proliferative activities. Eur J Med Chem 2019; 176:419-430. [DOI: 10.1016/j.ejmech.2019.05.035] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2019] [Revised: 05/08/2019] [Accepted: 05/12/2019] [Indexed: 12/16/2022]
|
19
|
Nam TK, Jang DO. Radical "On Water" Addition to the C═N Bond of Hydrazones: A Synthesis of Isoindolinone Derivatives. J Org Chem 2018; 83:7373-7379. [PMID: 29498284 DOI: 10.1021/acs.joc.7b03193] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
A radical "on water" addition to the C═N bond of hydrazones has been described. Hydrazone, diphenylsilane, alkyl iodide, and triethylborane afforded the corresponding addition products "on water" in good yields. A significant solvent effect was observed from the water. The developed protocol can be applied to the synthesis of 3-substituted isoindolinone derivatives. Moreover, the process offers environmentally benign tin-free radical reaction conditions.
Collapse
Affiliation(s)
- Tae Kyu Nam
- Department of Chemistry , Yonsei University , Wonju 26493 , Republic of Korea
| | - Doo Ok Jang
- Department of Chemistry , Yonsei University , Wonju 26493 , Republic of Korea
| |
Collapse
|
20
|
Soengas R, Belmonte Sánchez E, Iglesias MJ, López Ortiz F. Synthesis of P-Stereogenic Benzoazaphosphole 1-Oxides via Alkynylation of P-Stereogenic ortho-Aurated and ortho-Iodo Phosphinic Amides. ACS OMEGA 2018; 3:5116-5124. [PMID: 31458727 PMCID: PMC6641963 DOI: 10.1021/acsomega.8b00491] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Accepted: 04/03/2018] [Indexed: 06/10/2023]
Abstract
An efficient methodology for the synthesis of P-stereogenic dihydrobenzoazaphosphole 1-oxides via intramolecular 5-exo-dig alkyne hydroamination promoted by tetrabutylammonium fluoride is herein described. The required chiral o-alkynylphosphinic amide starting materials were prepared in high yields under very mild reaction conditions through alkynylation of P-stereogenic (O^C)-cyclometalated (phosphinic amide)dichlorogold(III) complexes and Sonogashira cross-coupling of ortho-iodo P-stereogenic phosphinic amide.
Collapse
|
21
|
Chessum NEA, Sharp SY, Caldwell JJ, Pasqua AE, Wilding B, Colombano G, Collins I, Ozer B, Richards M, Rowlands M, Stubbs M, Burke R, McAndrew PC, Clarke PA, Workman P, Cheeseman MD, Jones K. Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766). J Med Chem 2018; 61:918-933. [PMID: 29240418 PMCID: PMC5815658 DOI: 10.1021/acs.jmedchem.7b01406] [Citation(s) in RCA: 67] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2017] [Indexed: 01/03/2023]
Abstract
Demonstrating intracellular protein target engagement is an essential step in the development and progression of new chemical probes and potential small molecule therapeutics. However, this can be particularly challenging for poorly studied and noncatalytic proteins, as robust proximal biomarkers are rarely known. To confirm that our recently discovered chemical probe 1 (CCT251236) binds the putative transcription factor regulator pirin in living cells, we developed a heterobifunctional protein degradation probe. Focusing on linker design and physicochemical properties, we generated a highly active probe 16 (CCT367766) in only three iterations, validating our efficient strategy for degradation probe design against nonvalidated protein targets.
Collapse
Affiliation(s)
- Nicola E. A. Chessum
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| | - Swee Y. Sharp
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| | - John J. Caldwell
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| | - A. Elisa Pasqua
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| | - Birgit Wilding
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| | - Giampiero Colombano
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| | - Ian Collins
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| | - Bugra Ozer
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| | - Meirion Richards
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| | - Martin Rowlands
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| | - Mark Stubbs
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| | - Rosemary Burke
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| | - P. Craig McAndrew
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| | - Paul A. Clarke
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| | - Paul Workman
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| | - Matthew D. Cheeseman
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| | - Keith Jones
- Cancer Research
UK Cancer Therapeutics Unit at The Institute
of Cancer Research, London SW7 3RP, United Kingdom
| |
Collapse
|
22
|
Hu S, Yuan L, Yan H, Li Z. Design, synthesis and biological evaluation of Lenalidomide derivatives as tumor angiogenesis inhibitor. Bioorg Med Chem Lett 2017; 27:4075-4081. [DOI: 10.1016/j.bmcl.2017.07.046] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2017] [Revised: 07/15/2017] [Accepted: 07/18/2017] [Indexed: 12/11/2022]
|
23
|
Ríos-Tamayo R, Martín-García A, Alarcón-Payer C, Sánchez-Rodríguez D, de la Guardia AMDVD, García Collado CG, Jiménez Morales A, Jurado Chacón M, Cabeza Barrera J. Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy. Drug Des Devel Ther 2017; 11:2399-2408. [PMID: 28860711 PMCID: PMC5574598 DOI: 10.2147/dddt.s115456] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting. The combination of pomalidomide (POM) and dexamethasone is safe and effective in relapsed and refractory patients, even in those with high-risk cytogenetic features. Furthermore, it can be used in most patients without the need to adjust according to the degree of renal failure. In order to further improve the results, POM-based triplet therapies are currently used. This article highlights the most relevant issues of POM and POM-based combinations in the relapsed/refractory multiple myeloma setting, from a pharmacological and clinical point of view.
Collapse
Affiliation(s)
- Rafael Ríos-Tamayo
- Monoclonal Gammopathies Unit
- Department of Hematology, University Hospital Virgen de las Nieves, Granada, Spain
- Genomic Oncology Area, GENYO, Center for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, Spain
- Instituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
| | - Agustín Martín-García
- Department of Pharmacy
- Clinical Trials Unit, University Hospital Virgen de las Nieves, Granada, Spain
| | | | | | | | | | | | - Manuel Jurado Chacón
- Monoclonal Gammopathies Unit
- Department of Hematology, University Hospital Virgen de las Nieves, Granada, Spain
- Genomic Oncology Area, GENYO, Center for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, Spain
- Instituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
| | - José Cabeza Barrera
- Instituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain
- Department of Pharmacy
| |
Collapse
|
24
|
Frlan R, Gobec S. Evaluation of US 2016/0115161 A1: isoindoline compounds and methods of their use. Expert Opin Ther Pat 2017; 27:637-641. [PMID: 28452243 DOI: 10.1080/13543776.2017.1322954] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
INTRODUCTION Immunomodulatory drugs (IMIDs®) are small orally available molecules that modulate the immune system and other biological targets through multiple mechanisms of action and have been successfully used in the treatment of myelodysplastic syndrome and multiple myeloma. However, recent studies of their complex mechanism of action revealed their potential in autoimmune diseases and solid tumors, which intensified scientific interest in these compounds. Areas covered: This patent application claims new IMIDs for the treatment of cancer and disorders associated with angiogenesis and inflammation. Substitution of isoindolinone ring on position 5 with urea and amide linkers connected to different aromatic rings lead to very potent inhibitors of TNF-α production with antiproliferative activities against Nemalwa cells and against colorectal, pancreatic, prostate and breast cancer cell lines in sub-nano to low-nanomolar concentration range. Expert opinion: Substitution of position 5 on the isoindolinone ring, which is presented in this invention, is currently the hot spot of Celgene's research. Results of biological tests, which are superior over those of presently used IMIDs lenalidomide and pomalidomide, make these compounds viable leads for future development of new anticancer drugs against blood and solid cancers.
Collapse
Affiliation(s)
- Rok Frlan
- a The Chair of Pharmaceutical Chemistry , University of Ljubljana , Ljubljana , Slovenia
| | - Stanislav Gobec
- a The Chair of Pharmaceutical Chemistry , University of Ljubljana , Ljubljana , Slovenia
| |
Collapse
|
25
|
A convenient synthesis of 2-alkyl-3-aryl-2,3-dihydro-1H-isoindol-1-ones by the reaction of N-alkyl-N-[(2-bromophenyl)methyl]benzamides with butyllithium. Tetrahedron 2016. [DOI: 10.1016/j.tet.2016.06.082] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
26
|
Wester R, Sonneveld P. Innovations in treatment and response evaluation in multiple myeloma. Haematologica 2016; 101:518-20. [PMID: 27132277 DOI: 10.3324/haematol.2016.142737] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Ruth Wester
- Erasmus MC Cancer Institute (EMC), Rotterdam, The Netherlands
| | | |
Collapse
|
27
|
Krautwald S, Nilewski C, Mori M, Shiomi K, Ōmura S, Carreira EM. Bioisosteric Exchange of Csp3 -Chloro and Methyl Substituents: Synthesis and Initial Biological Studies of Atpenin A5 Analogues. Angew Chem Int Ed Engl 2016; 55:4049-53. [PMID: 26891236 DOI: 10.1002/anie.201511672] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2015] [Indexed: 11/06/2022]
Abstract
Asymmetric synthesis and initial biological studies of two analogues of a naturally occurring chlorinated antifungal agent, atpenin A5, are described. These analogues were selected on the basis of Cl→CH3 or H3 C→Cl exchanges in the side-chain of atpenin A5. The interchange of chloro and methyl substituents led to complex II inhibitors with equal IC50 values. This suggests that Cl↔Me bioisosteric exchange can be realized in aliphatic settings.
Collapse
Affiliation(s)
- Simon Krautwald
- Laboratorium für Organische Chemie, HCI H335, Eidgenössische Technische Hochschule Zürich, Vladimir-Prelog-Weg 3, 8093, Zürich, Switzerland
| | - Christian Nilewski
- Laboratorium für Organische Chemie, HCI H335, Eidgenössische Technische Hochschule Zürich, Vladimir-Prelog-Weg 3, 8093, Zürich, Switzerland
| | - Mihoko Mori
- Department of Drug Discovery Sciences, Kitasato Institute for Life Sciences and Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan
| | - Kazuro Shiomi
- Department of Drug Discovery Sciences, Kitasato Institute for Life Sciences and Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan.
| | - Satoshi Ōmura
- Department of Drug Discovery Sciences, Kitasato Institute for Life Sciences and Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan
| | - Erick M Carreira
- Laboratorium für Organische Chemie, HCI H335, Eidgenössische Technische Hochschule Zürich, Vladimir-Prelog-Weg 3, 8093, Zürich, Switzerland.
| |
Collapse
|
28
|
Krautwald S, Nilewski C, Mori M, Shiomi K, Ōmura S, Carreira EM. Bioisosteric Exchange of Csp3
-Chloro and Methyl Substituents: Synthesis and Initial Biological Studies of Atpenin A5 Analogues. Angew Chem Int Ed Engl 2016. [DOI: 10.1002/ange.201511672] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Simon Krautwald
- Laboratorium für Organische Chemie, HCI H335; Eidgenössische Technische Hochschule Zürich; Vladimir-Prelog-Weg 3 8093 Zürich Switzerland
| | - Christian Nilewski
- Laboratorium für Organische Chemie, HCI H335; Eidgenössische Technische Hochschule Zürich; Vladimir-Prelog-Weg 3 8093 Zürich Switzerland
| | - Mihoko Mori
- Department of Drug Discovery Sciences, Kitasato Institute for Life Sciences and Graduate School of Infection Control Sciences; Kitasato University; 5-9-1 Shirokane, Minato-ku Tokyo 108-8641 Japan
| | - Kazuro Shiomi
- Department of Drug Discovery Sciences, Kitasato Institute for Life Sciences and Graduate School of Infection Control Sciences; Kitasato University; 5-9-1 Shirokane, Minato-ku Tokyo 108-8641 Japan
| | - Satoshi Ōmura
- Department of Drug Discovery Sciences, Kitasato Institute for Life Sciences and Graduate School of Infection Control Sciences; Kitasato University; 5-9-1 Shirokane, Minato-ku Tokyo 108-8641 Japan
| | - Erick M. Carreira
- Laboratorium für Organische Chemie, HCI H335; Eidgenössische Technische Hochschule Zürich; Vladimir-Prelog-Weg 3 8093 Zürich Switzerland
| |
Collapse
|
29
|
New efficient synthesis of isoquinoline-1,3(2H,4H)-diones and isoindolin-1-ones via sequential Ugi/cyclization reaction. Tetrahedron 2016. [DOI: 10.1016/j.tet.2015.11.051] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
30
|
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nat Rev Drug Discov 2015; 14:693-720. [PMID: 26338155 DOI: 10.1038/nrd4592] [Citation(s) in RCA: 161] [Impact Index Per Article: 17.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Fibrosis, which leads to progressive loss of tissue function and eventual organ failure, has been estimated to contribute to ~45% of deaths in the developed world, and so new therapeutics to modulate fibrosis are urgently needed. Major advances in our understanding of the mechanisms underlying pathological fibrosis are supporting the search for such therapeutics, and the recent approval of two anti-fibrotic drugs for idiopathic pulmonary fibrosis has demonstrated the tractability of this area for drug discovery. This Review examines the pharmacology and structural information for small molecules being evaluated for lung, liver, kidney and skin fibrosis. In particular, we discuss the insights gained from the use of these pharmacological tools, and how these entities can inform, and probe, emerging insights into disease mechanisms, including the potential for future drug combinations.
Collapse
|
31
|
FERREIRA PAULOMICHELPINHEIRO, COSTA PATRICIAMARÇALDA, COSTA ARINICEDEMENEZES, LIMA DAISYJEREISSATIBARBOSA, DRUMOND RENATAROSADO, SILVA JURANDYDONASCIMENTO, MOREIRA DIOGORODRIGODEMAGALHÃES, OLIVEIRA FILHO GEVÂNIOBEZERRADE, FERREIRA JAMILEMAGALHÃES, QUEIROZ MARIAGORETTIRODRIGUESDE, LEITE ANACRISTINALIMA, PESSOA CLÁUDIA. Cytotoxic and toxicological effects of phthalimide derivatives on tumor and normal murine cells. ACTA ACUST UNITED AC 2015; 87:313-30. [DOI: 10.1590/0001-3765201520130345] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2013] [Accepted: 08/06/2014] [Indexed: 11/22/2022]
Abstract
Eleven phthalimide derivatives were evaluated with regards to their antiproliferative activity on tumor and normal cells and possible toxic effects. Cytotoxic analyses were performed against murine tumors (Sarcoma 180 and B-16/F-10 cells) and peripheral blood mononuclear cells (PBMC) using MTT and Alamar Blue assays. Following, the investigation of cytotoxicity was executed by flow cytometry analysis and antitumoral and toxicological potential by in vivo techniques. The molecules 3b, 3c, 4 and 5 revealed in vitro cytotoxicity against Sarcoma 180, B-16/F-10 and PBMC. Since compound 4 was the most effective derivative, it was chosen to detail the mechanism of action after 24, 48 and 72 h exposure (22.5 and 45 µM). Sarcoma 180 cells treated with compound 4 showed membrane disruption, DNA fragmentation and mitochondrial depolarization in a time- and dose-dependent way. Compounds 3c, 4 and 5 (50 mg/kg/day) did not inhibit in vivotumor growth. Compound 4-treated animals exhibited an increase in total leukocytes, lymphocytes and spleen relative weight, a decreasing in neutrophils and hyperplasia of spleen white pulp. Treated animals presented reversible histological changes. Molecule 4 had in vitro antiproliferative action possibly triggered by apoptosis, reversible toxic effects on kidneys, spleen and livers and exhibited immunostimulant properties that can be explored to attack neoplasic cells.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - CLÁUDIA PESSOA
- Universidade Federal do Ceará, Brasil; Fundação Oswaldo Cruz, Brasil
| |
Collapse
|
32
|
Natte K, Chen J, Li H, Neumann H, Beller M, Wu XF. Palladium-Catalyzed Carbonylation of 2-Bromoanilines with 2-Formylbenzoic Acid and 2-Halobenzaldehydes: Efficient Synthesis of Functionalized Isoindolinones. Chemistry 2014; 20:14184-8. [DOI: 10.1002/chem.201404446] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2014] [Indexed: 11/08/2022]
|
33
|
Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 2014; 512:49-53. [PMID: 25043012 PMCID: PMC4423819 DOI: 10.1038/nature13527] [Citation(s) in RCA: 664] [Impact Index Per Article: 66.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2013] [Accepted: 05/23/2014] [Indexed: 12/18/2022]
Abstract
In the 1950s, the drug thalidomide, administered as a sedative to pregnant women, led to the birth of thousands of children with multiple defects. Despite the teratogenicity of thalidomide and its derivatives lenalidomide and pomalidomide, these immunomodulatory drugs (IMiDs) recently emerged as effective treatments for multiple myeloma and 5q-deletion-associated dysplasia. IMiDs target the E3 ubiquitin ligase CUL4-RBX1-DDB1-CRBN (known as CRL4(CRBN)) and promote the ubiquitination of the IKAROS family transcription factors IKZF1 and IKZF3 by CRL4(CRBN). Here we present crystal structures of the DDB1-CRBN complex bound to thalidomide, lenalidomide and pomalidomide. The structure establishes that CRBN is a substrate receptor within CRL4(CRBN) and enantioselectively binds IMiDs. Using an unbiased screen, we identified the homeobox transcription factor MEIS2 as an endogenous substrate of CRL4(CRBN). Our studies suggest that IMiDs block endogenous substrates (MEIS2) from binding to CRL4(CRBN) while the ligase complex is recruiting IKZF1 or IKZF3 for degradation. This dual activity implies that small molecules can modulate an E3 ubiquitin ligase and thereby upregulate or downregulate the ubiquitination of proteins.
Collapse
|
34
|
Lewis acid-catalyzed cascade radical addition/cyclization for the synthesis of 3-substituted isoindolin-1-one derivatives. Tetrahedron Lett 2014. [DOI: 10.1016/j.tetlet.2014.03.023] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
35
|
|
36
|
Cantillo D, de Frutos O, Rincon JA, Mateos C, Kappe CO. A Scalable Procedure for Light-Induced Benzylic Brominations in Continuous Flow. J Org Chem 2013; 79:223-9. [DOI: 10.1021/jo402409k] [Citation(s) in RCA: 71] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- David Cantillo
- Institute
of Chemistry, University of Graz, Heinrichstrasse 28, A-8010 Graz, Austria
| | - Oscar de Frutos
- Centro de Investigación Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas-Madrid, Spain
| | - Juan A. Rincon
- Centro de Investigación Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas-Madrid, Spain
| | - Carlos Mateos
- Centro de Investigación Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas-Madrid, Spain
| | - C. Oliver Kappe
- Institute
of Chemistry, University of Graz, Heinrichstrasse 28, A-8010 Graz, Austria
| |
Collapse
|
37
|
Frutos-Pedreño R, González-Herrero P, Vicente J, Jones PG. Reactivity of Ortho-Palladated Benzamides toward CO, Isocyanides, and Alkynes. Synthesis of Functionalized Isoindolin-1-ones and 4,5-Disubstituted Benzo[c]azepine-1,3-diones. Organometallics 2013. [DOI: 10.1021/om4006406] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Roberto Frutos-Pedreño
- Grupo de Química Organometálica, Departamento
de Química Inorgánica, Facultad de Química, Universidad de Murcia, Apartado 4021, 30071 Murcia,
Spain
| | - Pablo González-Herrero
- Grupo de Química Organometálica, Departamento
de Química Inorgánica, Facultad de Química, Universidad de Murcia, Apartado 4021, 30071 Murcia,
Spain
| | - José Vicente
- Grupo de Química Organometálica, Departamento
de Química Inorgánica, Facultad de Química, Universidad de Murcia, Apartado 4021, 30071 Murcia,
Spain
| | - Peter G. Jones
- Institut für Anorganische und Analytische Chemie, Technische Universität Braunschweig, Postfach
3329, 38023 Braunschweig, Germany
| |
Collapse
|
38
|
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. Proc Natl Acad Sci U S A 2013; 110:12703-8. [PMID: 23858438 DOI: 10.1073/pnas.1307684110] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Thalidomide and its analog, Lenalidomide, are in current use clinically for treatment of multiple myeloma, complications of leprosy and cancers. An additional analog, Pomalidomide, has recently been licensed for treatment of multiple myeloma, and is purported to be clinically more potent than either Thalidomide or Lenalidomide. Using a combination of zebrafish and chicken embryos together with in vitro assays we have determined the relative anti-inflammatory activity of each compound. We demonstrate that in vivo embryonic assays Pomalidomide is a significantly more potent anti-inflammatory agent than either Thalidomide or Lenalidomide. We tested the effect of Pomalidomide and Lenalidomide on angiogenesis, teratogenesis, and neurite outgrowth, known detrimental effects of Thalidomide. We found that Pomalidomide, displays a high degree of cell specificity, and has no detectable teratogenic, antiangiogenic or neurotoxic effects at potent anti-inflammatory concentrations. This is in marked contrast to Thalidomide and Lenalidomide, which had detrimental effects on blood vessels, nerves, and embryonic development at anti-inflammatory concentrations. This work has implications for Pomalidomide as a treatment for conditions Thalidomide and Lenalidomide treat currently.
Collapse
|
39
|
Mamidyala SK, Cooper MA. Probing the reactivity of o-phthalaldehydic acid/methyl ester: synthesis of N-isoindolinones and 3-arylaminophthalides. Chem Commun (Camb) 2013; 49:8407-9. [DOI: 10.1039/c3cc43838d] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
40
|
Wustrow D, Zhou HJ, Rolfe M. Inhibition of Ubiquitin Proteasome System Enzymes for Anticancer Therapy. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 2013. [DOI: 10.1016/b978-0-12-417150-3.00014-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/01/2023]
|